The ustekinumab (Stelara; Janssen Biotech) biosimilar DMB-3115 (Imuldosa; Accord BioPharma) demonstrated clinical efficacy and safety comparable to the reference product through 52 weeks in a recent ...
DUESSELDORF/FRANKFURT, July 14 (Reuters) - German biotech group Morphosys expects to receive royalties from psoriasis drug guselkumab for five months this year, its ...
Stelara (ustekinumab) is indicated for moderate to severe psoriasis, active psoriatic arthritis, Crohn's disease, and ulcerative colitis. Janssen had previously reached agreements allowing competitors ...
In areas of high impact, 72% of patients with scalp psoriasis and 85% with genital psoriasis treated with icotrokinra achieved site-specific clear or almost clear skin at Week 52 in Phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback